Moderna (MRNA) Assets Average (2019 - 2026)

Moderna (MRNA) has reported Assets Average for 8 consecutive years, with $11.2 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets Average fell 9.16% year-over-year to $11.2 billion in Q2 2026; TTM through Jun 2026 was $11.2 billion, a 9.16% decrease from a year earlier, with the FY2025 full-year figure at $13.2 billion, down 18.69% from the prior year.
• Assets Average was $11.2 billion for Q2 2026 at Moderna, down from $11.9 billion in the prior quarter.
• Over five years, Assets Average peaked at $26.8 billion in Q2 2022 and troughed at $11.2 billion in Q2 2026.
• A 5-year average of $18.3 billion and a median of $16.9 billion in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average soared 160.99% in 2022 and decreased 29.67% in 2024, its largest moves.
• Over 5 years, Assets Average stood at $26.0 billion in 2022, then retreated by 27.04% to $18.9 billion in 2023, then dropped by 20.94% to $15.0 billion in 2024, then decreased by 18.27% to $12.2 billion in 2025, then dropped by 8.27% to $11.2 billion in 2026.
• The last three Assets Average figures came in at $11.2 billion (Q2 2026), $11.9 billion (Q1 2026), and $12.2 billion (Q4 2025), per Business Quant data.